POOLBEG PHARMA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.1 GBX | -0.76% |
|
+2.34% | +44.75% |
| 01/05 | Poolbeg Pharma Secures Full Patent in US for Immunomodulator II | MT |
| 01/05 | Poolbeg Pharma celebrates full patent approval for Immunomodulator II | AN |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 47.5 | 30.25 | 65.5 | 65.5 | - |
| Enterprise Value (EV) 1 | 47.5 | 14.06 | 45.25 | 59.3 | 65 |
| P/E ratio | -12.8 x | -6.44 x | -11.5 x | -10.1 x | -10.9 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | -2.83 x | -9.71 x | -9.12 x | -10.5 x |
| EV / FCF | - | -2.83 x | -9.81 x | -10.1 x | -11.4 x |
| FCF Yield | - | -35.3% | -10.2% | -9.95% | -8.77% |
| Price to Book | - | 1.65 x | 5.06 x | 8.19 x | 32.8 x |
| Nbr of stocks (in thousands) | 5,00,000 | 5,00,000 | 5,00,000 | 5,00,000 | - |
| Reference price 2 | 0.0950 | 0.0605 | 0.1310 | 0.1310 | 0.1310 |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | - | -4.96 | -4.66 | -6.5 | -6.2 |
| EBIT 1 | - | -4.986 | -4.686 | -6.528 | -6.285 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -4.777 | -4.505 | -6.375 | -6.235 |
| Net income 1 | -2.336 | -4.686 | -3.931 | -6.375 | -6.235 |
| Net margin | - | - | - | - | - |
| EPS 2 | -0.007400 | -0.009400 | -0.007900 | -0.0130 | -0.0120 |
| Free Cash Flow 1 | - | -4.965 | -5.58 | -5.9 | -5.7 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 16.2 | 10.8 | 6.2 | 0.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -4.97 | -5.58 | -5.9 | -5.7 |
| ROE (net income / shareholders' equity) | - | -22.9% | -43.5% | -77.6% | -318% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.0400 | 0.0300 | 0.0200 | 0 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 0.6 | 0.1 | 0.1 | 0.1 |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.131
GBP
Average target price
0.21
GBP
Spread / Average Target
+60.31%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +44.75% | 83.49M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- POLB Stock
- Financials Poolbeg Pharma PLC
